New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2014
07:17 EDTCFN, COV, MASI, BCRCovidien looking to make acquisitions, NY Times says
Medical device maker Covidien plans to use a portion of its free cash flow for strategic acquisitions in the near-term, the company's CEO said, The New York Times reported yesterday.. Reference Link
News For COV;BCR;MASI;CFN From The Last 14 Days
Check below for free stories on COV;BCR;MASI;CFN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
09:23 EDTCOVBarclays medical supplies/devices analysts hold analyst/industry conference call
Subscribe for More Information
April 14, 2014
08:05 EDTCOVCovidien announces FDA 510(k) clearance for Kangaroo feeding tube
Subscribe for More Information
April 11, 2014
11:42 EDTCOVCovidien liability from recall appears limited, says Brean Capital
Subscribe for More Information
08:10 EDTCOVCovidien implements voluntary recall of devices
Subscribe for More Information
April 8, 2014
07:35 EDTBCRNeedham to hold a conference
Life Sciences Conference is being held in New York on April 8-9.
07:26 EDTCOVElsevier Business Intelligence to hold a conference
Subscribe for More Information
April 7, 2014
10:00 EDTBCROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:31 EDTMASIMasimo PVI helps clinicians optimize fluid administration
Subscribe for More Information
07:58 EDTBCRMedtronic data positive for C.R. Bard, says Barclays
Barclays said Medtronic's (MDT) better than expected drug coated balloon data could have a positive class effect that benefits C.R. Bard (BCR). The firm reiterates its Overweight rating C.R. Bard and raised its price target to $165 from $160. Note that BofA/Merrill downgraded C.R. Bard to Neutral from Buy following the Medtronic's news.
07:38 EDTBCRMedtronic data should lead to approval of drug-coated balloon, says Wells Fargo
Subscribe for More Information
07:26 EDTBCRC.R. Bard downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use